7 results about "Toremifene" patented technology

The present invention belongs to the technical field of pharmaceutical preparations and specifically relates to a toremifene citrate liposome, a preparation method, and a preparation. The present invention encapsulates toremifene citrate in a lipid carrier composed of toremifene citrate, peanut lecithin, cholesterol, and calcium propionate. The preparation method is optimized to provide a toremifene citrate liposome with high drug loading, high encapsulation efficiency, and high stability. The liposome is then further prepared with pharmaceutically acceptable excipients into a toremifene citrate preparation, which improves oral bioavailability, reduces impurity content, and improves the stability of the preparation.

The present application relates to the use of a VRAC modulator of formula I or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of cancer in combination with an anti-hormone agent selected from the group consisting of: a. An anti-estrogen selected from fulvestrant, tamoxifen, toremifene and clomifene; and b. An anti-progestational hormone selected from the group consisting of mifepristone, ulipristal acetate, ensipristone, liropristone, and onapristone. # imgabs0 #

The application relates to the technical field of compound synthesis, and particularly discloses a preparation method of an intermediate of toripalimab citrate, which comprises the following steps: a first reaction of cinnamyl alcohol and diethyl phosphite in an organic solvent to obtain a first reactant; and a second reaction of the obtained first reactant, alkali and 4-[2-(N,N-dimethylamino)ethoxy]benzophenone to obtain a second reactant containing the intermediate I of toripalimab citrate. A brand-new process route is developed, raw materials used in the route are all easy to obtain, the whole reaction route is short, operation is simple, reaction conditions are mild and safe, the yield of the obtained intermediate I of toripalimab citrate is high, the purity is also high, the total yield is more than 80%, the purity is more than 99.9%, and industrialized production can be realized.

This invention relates to the treatment of breast cancer in a subject, and the subject can be either a male or female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed selective estrogen receptor modulator (SERM) (tamoxifen, toremifene, raloxifene), gonadotropin-releasing hormone (GnRH) agonist (goserelin), aromatase inhibitor (AI) (letrozole, anastrozole, exemestane), cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor (palbociclib (Ibrance), ribociclib (Kisqali), lerociclib, abemaciclib (Vorzenio), trilaciclib, lerociclib), mTOR inhibitor (everolimus), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), alpelisib (Piqray) (an inhibitor of phosphatidylinositol-3-kinase subunit alpha (PI3Kα)), lapatinib, neratinib (Nerlynx), olaparib (Lynparza) (an inhibitor of the enzyme poly ADP ribose polymerase (PARP)), bevacizumab (Avastin), and / or fulvestrant treatments; metastasis in a subject suffering from breast cancer; HER2-positive; treating a subject suffering from ER mutant expressing breast cancer and / or treating breast cancer in a subject, by first determining the 18F-16β-fluoro-5α-dihydrotestosterone (18F-DHT) tumor uptake and identifying said subject as having AR-positive breast cancer based on 18F-DHT tumor uptake, comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound and a cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor.

1. Name of the product of this design: packaging box (toremifene citrate tablets). 2. Purpose of the product of this design: an outer packaging box for medicines. 3. The design key points of this appearance design product are: the combination of shape, pattern and color. 4. The picture or photo that best illustrates the key points of the design: main view. 5. The design for which protection is sought includes color.

The present disclosure provides a composition comprising a compound of Formula X, Formula Y and / or Formula Z, or pharmaceutically acceptable salts thereof, for use in inhibiting Galectin-3. Formula X relates to Tosufloxacin tosylate; Formula Y relates to Nelfinavir mesylate; and Formula Z relates to Toremifene citrate. The composition may be for use in the treatment and / or prevention of a disease, disorder, state or condition wherein inhibiting Galectin-3 would be beneficial for the treatment and / or prevention of the disease, disorder, state or condition. The disease, disorder, state or condition may be cancer, cancer metastasis, fibrosis, inflammation, diabetes and / or one or more other disease, disorder, state or condition affected and / or mediated by Galectin-3. An in vitro method of inhibiting Galectin-3 and a method of inhibiting Galectin-3 in a biological sample comprising administering the composition is also disclosed. A kit, combination therapy or pharmaceutical composition comprising a compound of Formula I and / or Formula II is also provided.

The invention discloses a toremifene citrate tablet and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The toremifene citrate tablet is prepared from a toremifene citrate solid dispersion, a filling agent, a disintegrating agent, a lubricating agent and a flow aid, wherein the toremifene citrate solid dispersion is prepared by compounding toremifene citrate, copovidone, quercetin and hydroxypropyl methylcellulose K100M in proportion. The preparation method comprises preparation of the toremifene citrate solid dispersion and preparation of the tablet. Compared with the prior art, the toremifene citrate tablet can play a slow release effect, is high in bioavailability and is suitable for industrial mass production.